FXG:Resp (Asp+) is a multiplex, real-time PCR-based product used for the diagnosis of Aspergillus and Pneumocystis fungi, the common causative agents of life-threatening respiratory infections
FXG: Resp (Asp+) is a diagnostic product that provides clinicians with reliable and accurate results for two of the most common fungal diseases in less than half a day, enabling them to make faster decisions and to potentially start treatment earlier than was possible before.
The showcase follows successful clinical evaluation of FXG:Resp (Asp+) and the CE marking of Myconostica's efficient fungal DNA extraction kit (MycXtra) to European member countries.
Myconostica plans further performance evaluation studies to support the products.
Both are being showcased at the prestigious Trends in Medical Mycology Conference (Timm), Torino, Italy.
Over ten million people are at risk of life threatening respiratory fungal infections in Europe and North America each year.
However, current methods for fungal diagnostics are inherently slow and imprecise, relying mainly on culturing patient samples (which takes overs three days).
This may lead to a poor diagnosis and contribute to a high mortality.
In contrast, in less than half a day Myconostica's FXG:Resp (Asp+) diagnostic product accurately, specifically and reliably identifies whether the fungi Aspergillus and/or Pneumocystis are causing the infection.
Commenting on the CE marking and showcasing of Myconostica's first products, David Denning, chief executive and research director of Myconostica said: "Attaining CE mark approval for MycXtra is an important step for Myconostica and the FXG product range will answer the need for rapid diagnostics for disease-causing fungi in respiratory and other clinically relevant tissues and body fluids".
Richard Morgan, chief executive officer of Amphion Innovations, a leading investor in Myconostica, said: "CE marking of MycXtra, and FXG:Resp (Asp+) nearing the market, represents a major milestone for the company".
"These products will have a extreme impact not only on the field of fungal diagnostics but also on the patients who currently have a lengthy wait for their test results".
Myconostica says its FXG family of diagnostic tests accurately, specifically and reliably identifies fungal causes of infection in less than half a day to enable doctors and clinicians to diagnose and treat life-threatening fungal infections, thereby reducing patient mortality rate, hospital residence time and healthcare costs.
The company was founded by David Denning, professor of medicine and medical mycology, University Hospital South Manchester.
Today, it employs a team of research, product development and marketing professionals and managers who are developing and supplying a rich pipeline of innovative products and services for the diagnosis of life-threatening fungal diseases that will be launched over the next years.
